Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio (NASDAQ: IBIO) reported preclinical obese non-human primate data for IBIO-610, a potential first-in-class Activin E antibody for obesity. A single dose reduced active Activin E by 98% at week 4 and 97% at week 8, with levels below assay limits.
Combined with semaglutide, IBIO-610 increased visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone, suggesting fat-selective weight loss potential and infrequent dosing. Full results will be presented at the 2026 EASD Annual Meeting in Milan.
iBio (NASDAQ: IBIO) announced participation in two upcoming healthcare investor conferences. CEO/CSO Martin Brenner and CFO Felipe Duran will present and hold investor meetings.
The events include the Jefferies Global Healthcare Conference on June 4, 2026, in New York and the Leerink Partners Therapeutics Forum on July 14–15, 2026, in Boston.
iBio (NASDAQ: IBIO) dosed the first participant in its Phase 1 trial of IBIO-600, becoming a clinical-stage company. IBIO-600 is a long-acting anti-myostatin/GDF11 monoclonal antibody being tested in adults with overweight and obesity for safety, tolerability, PK/PD, and exploratory body composition effects.
iBio (NASDAQ:IBIO) reported Q3 FY2026 results and a broad pipeline update. The company received Australian regulatory and ethics clearance to start a first-in-human Phase 1 trial of obesity candidate IBIO-600, with initial dosing in overweight and obese adults expected in Q2 calendar 2026.
iBio expanded its pipeline into PH-HFpEF with a selective bispecific antibody and reported new obese NHP data for IBIO-610, showing 6.7% visceral fat and 5.2% total fat mass reductions in a small, non-powered study. Q3 revenue was zero; R&D rose to $3.3M and G&A to $5.1M, including a $2.5M IBIO-101 impairment. Cash, equivalents and debt securities were $74.8M at March 31, 2026, plus $17M gross from Q4 FY2026 warrant exercises, extending the cash runway into Q4 FY2028.
iBio (NASDAQ:IBIO) appointed Elizabeth Stoner, M.D., M.S., to its Board of Directors and to the Compensation Committee on May 8, 2026, concurrent with the departure of director Eef Schimmelpennink.
Dr. Stoner brings over 35 years of R&D leadership, industry and board experience and will support iBio as it begins its first human clinical trial for IBIO-610, IBIO-600 and other assets.
iBio (NASDAQ: IBIO) received Clinical Trial Notification acknowledgement from Australia’s TGA and Human Research Ethics Committee approval to start a Phase 1 first-in-human study of IBIO-600. The randomized, double-blind, placebo-controlled single ascending dose trial targets overweight and obese adults.
First participant dosing is expected in 2Q 2026. IBIO-600 targets myostatin and GDF11 to preserve lean mass, is engineered for infrequent dosing (potentially 2–4 times per year) and showed a 40–52 day half-life and up to 5.1% lean-mass gains in non-human primates, with accompanying fat-mass reductions in preclinical studies.
iBio (NASDAQ:IBIO) will host a corporate update call on March 17, 2026 at 4:00 p.m. ET to discuss expansion into pulmonary hypertension associated with HFpEF (PH-HFpEF) and its engineered selective bispecific antibody program.
iBio expects to select an optimized bispecific development candidate in Q3 2026 before starting IND-enabling activities.
iBio (NASDAQ: IBIO) reported preclinical body composition data for IBIO-610 in obese non-human primates showing a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass after two once-every-eight-week doses, with a slight uptick in lean mass.
iBio also reported an extended 33.2-day half-life in obese NHPs and a projected human half-life up to 100 days, supporting potential twice-yearly dosing; full dataset and additional biomarker analyses will be presented at scientific conferences in 2026.
iBio (NASDAQ: IBIO) announced executive participation in two investor conferences: a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:00 p.m. ET, and a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 4:20 p.m. ET in Miami.
Martin Brenner, DVM, Ph.D., CEO and CSO, and Felipe Duran, CFO, will present and be available for one-on-one meetings; livestreams and replays will be accessible via the investor site for 90 days.
iBio (NASDAQ:IBIO) reported Q2 FY2026 results and a corporate update on Feb 10, 2026. The company closed a $26 million PIPE financing led by Frazier Life Sciences and received net proceeds of ~$24.4 million, extending cash runway into Q3 FY2028. Cash, cash equivalents and debt investments totaled $52.7 million as of Dec 31, 2025.
Preclinical progress includes NHP data for IBIO-610 (predicted human half-life up to 100 days), IBIO-600 toxicology nearing completion with Phase 1a planned in H1 2026, and ongoing CMC/toxicology to support IBIO-610 human trials in early 2027.